Diagnosis of cardiac sarcoidosis: histological evidence vs. imaging

References

• Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet. 2003;361(9363):1111–1118. doi: 10.1016/S0140-6736(03)12888-7
   PubMed Web of Science ®Google Scholar
• Hulten E, Agarwal V, Cahill M, et al. Presence of late gadolinium enhancement by cardiac magnetic resonance among patients with suspected cardiac sarcoidosis is associated with adverse cardiovascular prognosis: a systematic review and meta-analysis. Circ Cardiovasc Imaging. 2016;9(9):e005001. doi: 10.1161/CIRCIMAGING.116.005001
   PubMed Web of Science ®Google Scholar
• Patel MR, Cawley PJ, Heitner JF, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation. 2009;120(20):1969–1977. doi: 10.1161/CIRCULATIONAHA.109.851352
   PubMed Web of Science ®Google Scholar
• Birnie DH, Nery PB, Ha AC, et al. Cardiac Sarcoidosis. J Am Coll Cardiol. 2016;68(4):411–421. doi: 10.1016/j.jacc.2016.03.605
   PubMed Web of Science ®Google Scholar
• Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11(7):1305–1323. doi: 10.1016/j.hrthm.2014.03.043
   PubMed Web of Science ®Google Scholar
• Iwai K, Tachibana T, Takemura T, et al. Pathological studies on sarcoidosis autopsy. I. Epidemiological features of 320 cases in Japan. Acta Pathol Jpn. 1993;43(7–8):372–376. doi: 10.1111/j.1440-1827.1993.tb01148.x
   PubMedGoogle Scholar
• Kandolin R, Lehtonen J, Graner M, et al. Diagnosing isolated cardiac sarcoidosis. J Intern Med. 2011;270(5):461–468. doi: 10.1111/j.1365-2796.2011.02396.x
   PubMed Web of Science ®Google Scholar
• Yoshida Y, Morimoto S, Hiramitsu S, et al. Incidence of cardiac sarcoidosis in Japanese patients with high-degree atrioventricular block. Am Heart J. 1997;134(3):382–386. doi: 10.1016/S0002-8703(97)70070-X
   PubMed Web of Science ®Google Scholar
• Uemura A, Morimoto S, Hiramitsu S, et al. Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies. Am Heart J. 1999;138(2):299–302. doi: 10.1016/S0002-8703(99)70115-8
   PubMed Web of Science ®Google Scholar
• Blankstein R, Osborne M, Naya M, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol. 2014;63(4):329–336. doi: 10.1016/j.jacc.2013.09.022
   PubMed Web of Science ®Google Scholar
• Omote K, Naya M, Koyanagawa K, et al. (18)F-FDG uptake of the right ventricle is an important predictor of histopathologic diagnosis by endomyocardial biopsy in patients with cardiac sarcoidosis. J Nucl Cardiol. 2020;27(6):2135–2143. doi: 10.1007/s12350-018-01541-7
   PubMed Web of Science ®Google Scholar
• Ezzeddine FM, Kapa S, Rosenbaum A, et al. Electrogram-guided endomyocardial biopsy yield in patients with suspected cardiac sarcoidosis and relation to outcomes. J Cardiovasc Electrophysiol. 2021;32(9):2486–2495. doi: 10.1111/jce.15191
   PubMed Web of Science ®Google Scholar
• Liu J, Ma P, Lai L, et al. Transcriptional and immune landscape of cardiac sarcoidosis. Circ Res. 2022;131(8):654–669. doi: 10.1161/CIRCRESAHA.121.320449
   PubMed Web of Science ®Google Scholar
• Tana C, Mantini C, Donatiello I, et al. Clinical features and diagnosis of cardiac sarcoidosis. J Clin Med. 2021;10(9):10. doi: 10.3390/jcm10091941
   Web of Science ®Google Scholar
• Terasaki F, Azuma A, Anzai T, et al. JCS 2016 guideline on diagnosis and treatment of cardiac sarcoidosis - digest version. Circ J. 2019;83:2329–2388.
   PubMed Web of Science ®Google Scholar
• Kennel PJ, Raza F, Kim J, et al. A case series on inflammatory cardiomyopathy and suspected cardiac sarcoidosis: role of cardiac PET in management. Eur Heart J Case Rep. 2020;4(4):1–9. doi: 10.1093/ehjcr/ytaa146
   PubMedGoogle Scholar
• Kitai T, Nabeta T, Naruse Y, et al. Comparisons between biopsy-proven versus clinically diagnosed cardiac sarcoidosis. Heart. 2022;108(23):1887–1894. doi: 10.1136/heartjnl-2022-320932
   PubMed Web of Science ®Google Scholar
• Okada DR, Bravo PE, Vita T, et al. Isolated cardiac sarcoidosis: a focused review of an under-recognized entity. J Nucl Cardiol. 2018;25(4):1136–1146. doi: 10.1007/s12350-016-0658-1
   PubMed Web of Science ®Google Scholar
• Sperry BW, Oldan J, Hachamovitch R, et al. Insights into biopsy-proven cardiac sarcoidosis in patients with heart failure. J Heart Lung Transplant. 2016;35(3):392–393. doi: 10.1016/j.healun.2015.12.005
   PubMed Web of Science ®Google Scholar
• Sato K, Kawamatsu N, Yamamoto M, et al. Utility of updated Japanese Circulation Society guidelines to diagnose isolated cardiac sarcoidosis. J Am Heart Assoc. 2022;11(13):e025565. doi: 10.1161/JAHA.122.025565
   PubMed Web of Science ®Google Scholar
• Uemura A, Morimoto S, Kato Y, et al. Relationship between basal thinning of the interventricular septum and atrioventricular block in patients with cardiac sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2005;22(1):63–65. doi: 10.1007/s11083-005-9006-9
   PubMed Web of Science ®Google Scholar
• Rosenbaum AN, Kolluri N, Elwazir MY, et al. Identification of a novel presumed cardiac sarcoidosis category for patients at high risk of disease. Int J Cardiol. 2021;335:66–72. doi: 10.1016/j.ijcard.2021.04.022
   PubMed Web of Science ®Google Scholar
• Miki Y, Nakamura K, Sasaki T, et al. Hypertrophic cardiomyopathy complicated by cardiac sarcoidosis diagnosed by both the morphological abnormalities and the time course of the disease. Int Heart J. 2021;62(1):201–206. doi: 10.1536/ihj.20-552
   PubMed Web of Science ®Google Scholar
• Mathias IS, Oliveira Lima Filho JO, Culver DA, et al. Case report of isolated cardiac sarcoidosis presenting as hypertrophic obstructive cardiomyopathy—a clinical picture printed on lenticular paper. Eur Heart J Case Rep. 2021;5(6):ytab208. doi: 10.1093/ehjcr/ytab208
   PubMedGoogle Scholar
• Aoyama R, Takano H, Kobayashi Y, et al. Evaluation of myocardial glucose metabolism in hypertrophic cardiomyopathy using 18F-fluorodeoxyglucose positron emission tomography. PLoS One. 2017;12(11):e0188479. doi: 10.1371/journal.pone.0188479
   PubMed Web of Science ®Google Scholar
• Calkins H, Corrado D, Marcus F. Risk stratification in arrhythmogenic right ventricular cardiomyopathy. Circulation. 2017;136(21):2068–2082. doi: 10.1161/CIRCULATIONAHA.117.030792
   PubMed Web of Science ®Google Scholar
• Steckman DA, Schneider PM, Schuller JL, et al. Utility of cardiac magnetic resonance imaging to differentiate cardiac sarcoidosis from arrhythmogenic right ventricular cardiomyopathy. Am J Cardiol. 2012;110(4):575–579. doi: 10.1016/j.amjcard.2012.04.029
   PubMed Web of Science ®Google Scholar
• Sedaghat-Hamedani F, Kayvanpour E, Hamed S, et al. The chameleon of cardiology: cardiac sarcoidosis before and after heart transplantation. ESC Heart Fail. 2020;7(2):692–696. doi: 10.1002/ehf2.12581
   PubMed Web of Science ®Google Scholar
• Vasaiwala SC, Finn C, Delpriore J, et al. Prospective study of cardiac sarcoid mimicking arrhythmogenic right ventricular dysplasia. J Cardiovasc Electrophysiol. 2009;20(5):473–476. doi: 10.1111/j.1540-8167.2008.01351.x
   PubMed Web of Science ®Google Scholar
• Philips B, Madhavan S, James CA, et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy and cardiac sarcoidosis: distinguishing features when the diagnosis is unclear. Circ Arrhythm Electrophysiol. 2014;7(2):230–236. doi: 10.1161/CIRCEP.113.000932
   PubMed Web of Science ®Google Scholar
• Gasperetti A, Rossi VA, Chiodini A, et al. Differentiating hereditary arrhythmogenic right ventricular cardiomyopathy from cardiac sarcoidosis fulfilling 2010 ARVC task force criteria. Heart Rhythm. 2021;18(2):231–238. doi: 10.1016/j.hrthm.2020.09.015
   PubMed Web of Science ®Google Scholar
• Protonotarios A, Wicks E, Ashworth M, et al. Prevalence of (18)F-fluorodeoxyglucose positron emission tomography abnormalities in patients with arrhythmogenic right ventricular cardiomyopathy. Int J Cardiol. 2019;284:99–104. doi: 10.1016/j.ijcard.2018.10.083
   PubMed Web of Science ®Google Scholar
• Okura Y, Dec GW, Hare JM, et al. A clinical and histopathologic comparison of cardiac sarcoidosis and idiopathic giant cell myocarditis. J Am Coll Cardiol. 2003;41(2):322–329. doi: 10.1016/S0735-1097(02)02715-8
   PubMed Web of Science ®Google Scholar
• Litovsky SH, Burke AP, Virmani R. Giant cell myocarditis: an entity distinct from sarcoidosis characterized by multiphasic myocyte destruction by cytotoxic T cells and histiocytic giant cells. Mod Pathol. 1996;9(12):1126–1134.
   PubMed Web of Science ®Google Scholar
• Davies MJ, Pomerance A, Teare RD. Idiopathic giant cell myocarditis--a distinctive clinico-pathological entity. Br Heart J. 1975;37(2):192–195. doi: 10.1136/hrt.37.2.192
   PubMedGoogle Scholar
• Davidoff R, Palacios I, Southern J, et al. Giant cell versus lymphocytic myocarditis. A comparison of their clinical features and long-term outcomes. Circulation. 1991;83(3):953–961. doi: 10.1161/01.CIR.83.3.953
   PubMed Web of Science ®Google Scholar
• Nakasuka K, Ito S, Miyata K, et al. A case of idiopathic giant cell myocarditis with a past history of sarcoidosis. J Cardiol Cases. 2014;9(1):35–39. doi: 10.1016/j.jccase.2013.09.004
   PubMedGoogle Scholar
• Lamacie MM, Almufleh A, Nair V, et al. Serial 18 F-Fluorodeoxyglucose positron emission tomography imaging in a patient with giant cell myocarditis. Circ Cardiovasc Imaging. 2020;13(2):e009940. doi: 10.1161/CIRCIMAGING.119.009940
   PubMed Web of Science ®Google Scholar
• Nordenswan HK, Lehtonen J, Ekstrom K, et al. Manifestations and outcome of cardiac sarcoidosis and idiopathic giant cell myocarditis by 25-year nationwide cohorts. J Am Heart Assoc. 2021;10(6):e019415. doi: 10.1161/JAHA.120.019415
   PubMed Web of Science ®Google Scholar
• Smith ED, Lakdawala NK, Papoutsidakis N, et al. Desmoplakin cardiomyopathy, a fibrotic and inflammatory form of cardiomyopathy distinct from typical dilated or arrhythmogenic right ventricular cardiomyopathy. Circulation. 2020;141(23):1872–1884. doi: 10.1161/CIRCULATIONAHA.119.044934
   PubMed Web of Science ®Google Scholar
• Reza N, Levin MG, Vidula MK, et al. Prevalence of pathogenic variants in dilated cardiomyopathy–associated genes in patients evaluated for cardiac sarcoidosis. Circ Genom Precis Med. 2023;16(4):409–411. doi: 10.1161/CIRCGEN.122.003850
   PubMed Web of Science ®Google Scholar
• Divakaran S, Stewart GC, Lakdawala NK, et al. Diagnostic accuracy of advanced imaging in cardiac sarcoidosis. Circ Cardiovasc Imaging. 2019;12(6):e008975. doi: 10.1161/CIRCIMAGING.118.008975
   PubMed Web of Science ®Google Scholar
• Tanaka TD, Nagai T, Nagoshi T, et al. Diagnosis of cardiac sarcoidosis despite negative findings on serial late gadolinium enhancement with cardiac magnetic resonance imaging/(18)F-fluorodeoxyglucose positron emission tomography examinations. J Nucl Cardiol. 2020;27(6):2149–2153. doi: 10.1007/s12350-019-01968-6
   PubMed Web of Science ®Google Scholar
• Slart R, Glaudemans A, Lancellotti P, et al. A joint procedural position statement on imaging in cardiac sarcoidosis: from the cardiovascular and inflammation & infection committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology. J Nucl Cardiol. 2018;25(1):298–319. doi: 10.1007/s12350-017-1043-4
   PubMed Web of Science ®Google Scholar
• Ise T, Hasegawa T, Morita Y, et al. Extensive late gadolinium enhancement on cardiovascular magnetic resonance predicts adverse outcomes and lack of improvement in LV function after steroid therapy in cardiac sarcoidosis. Heart. 2014;100(15):1165–1172. doi: 10.1136/heartjnl-2013-305187
   PubMed Web of Science ®Google Scholar
• Crawford T, Mueller G, Sarsam S, et al. Magnetic resonance imaging for identifying patients with cardiac sarcoidosis and preserved or mildly reduced left ventricular function at risk of ventricular arrhythmias. Circ Arrhythm Electrophysiol. 2014;7(6):1109–1115. doi: 10.1161/CIRCEP.113.000156
   PubMed Web of Science ®Google Scholar
• Velangi PS, Chen KA, Kazmirczak F, et al. Right ventricular abnormalities on cardiovascular magnetic resonance imaging in patients with sarcoidosis. JACC Cardiovasc Imaging. 2020;13(6):1395–1405. doi: 10.1016/j.jcmg.2019.12.011
   PubMed Web of Science ®Google Scholar
• Athwal PSS, Chhikara S, Ismail MF, et al. Cardiovascular magnetic resonance imaging phenotypes and long-term outcomes in patients with suspected cardiac sarcoidosis. JAMA Cardiol. 2022;7(10):1057–1066. doi: 10.1001/jamacardio.2022.2981
   PubMed Web of Science ®Google Scholar
• Puntmann VO, Isted A, Hinojar R, et al. T1 and T2 mapping in recognition of early cardiac involvement in systemic sarcoidosis. Radiology. 2017;285(1):63–72. doi: 10.1148/radiol.2017162732
   PubMed Web of Science ®Google Scholar
• Crouser ED, Ono C, Tran T, et al. Improved detection of cardiac sarcoidosis using magnetic resonance with myocardial T2 mapping. Am J Respir Crit Care Med. 2014;189(1):109–112. doi: 10.1164/rccm.201309-1668LE
   PubMed Web of Science ®Google Scholar
• Ferreira VM, Schulz-Menger J, Holmvang G, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol. 2018;72(24):3158–3176. doi: 10.1016/j.jacc.2018.09.072
   PubMed Web of Science ®Google Scholar
• Greulich S, Gatidis S, Grani C, et al. Hybrid cardiac magnetic resonance/fluorodeoxyglucose positron emission tomography to differentiate active from chronic cardiac sarcoidosis. JACC Cardiovasc Imaging. 2022;15(3):445–456. doi: 10.1016/j.jcmg.2021.08.018
   PubMed Web of Science ®Google Scholar
• Orii M, Hirata K, Tanimoto T, et al. Comparison of cardiac MRI and 18F-FDG positron emission tomography manifestations and regional response to corticosteroid therapy in newly diagnosed cardiac sarcoidosis with complete heart block. Heart Rhythm. 2015;12(12):2477–2485. doi: 10.1016/j.hrthm.2015.06.032
   PubMed Web of Science ®Google Scholar
• Ishida Y, Yoshinaga K, Miyagawa M, et al. Recommendations for (18)F-fluorodeoxyglucose positron emission tomography imaging for cardiac sarcoidosis: Japanese Society of Nuclear Cardiology recommendations. Ann Nucl Med. 2014;28(4):393–403. doi: 10.1007/s12149-014-0806-0
   PubMed Web of Science ®Google Scholar
• Bois JP, Muser D, Chareonthaitawee P. PET/CT evaluation of cardiac sarcoidosis. PET Clin. 2019;14(2):223–232. doi: 10.1016/j.cpet.2018.12.004
   PubMed Web of Science ®Google Scholar
• Huang S, Kunchakarra S, Rathod A, et al. Is positron emission tomography enough to rule out cardiac sarcoidosis? A case report. Eur Heart J Case Rep. 2021;5(9):ytab300. doi: 10.1093/ehjcr/ytab300
   PubMedGoogle Scholar
• Wicks EC, Menezes LJ, Barnes A, et al. Diagnostic accuracy and prognostic value of simultaneous hybrid 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging in cardiac sarcoidosis. Eur Heart J Cardiovasc Imaging. 2018;19(7):757–767. doi: 10.1093/ehjci/jex340
   PubMed Web of Science ®Google Scholar
• Ning N, Guo HH, Iagaru A, et al. Serial cardiac FDG-PET for the diagnosis and therapeutic guidance of patients with cardiac sarcoidosis. J Card Fail. 2019;25(4):307–311. doi: 10.1016/j.cardfail.2019.02.018
   PubMed Web of Science ®Google Scholar
• Osborne MT, Hulten EA, Singh A, et al. Reduction in (1)(8)F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis. J Nucl Cardiol. 2014;21(1):166–174. doi: 10.1007/s12350-013-9828-6
   PubMed Web of Science ®Google Scholar
• Muser D, Santangeli P, Castro SA, et al. Prognostic role of serial quantitative evaluation of (18)F-fluorodeoxyglucose uptake by PET/CT in patients with cardiac sarcoidosis presenting with ventricular tachycardia. Eur J Nucl Med Mol Imaging. 2018;45(8):1394–1404. doi: 10.1007/s00259-018-4001-8
   PubMed Web of Science ®Google Scholar
• Blankstein R, Waller AH. Evaluation of known or suspected cardiac sarcoidosis. Circ Cardiovasc Imaging. 2016;9(3):e000867. doi: 10.1161/CIRCIMAGING.113.000867
   PubMed Web of Science ®Google Scholar
• Schouver ED, Moceri P, Doyen D, et al. Early detection of cardiac involvement in sarcoidosis with 2-dimensional speckle-tracking echocardiography. Int J Cardiol. 2017;227:711–716. doi: 10.1016/j.ijcard.2016.10.073
   PubMed Web of Science ®Google Scholar
• Kouranos V, Tzelepis GE, Rapti A, et al. Complementary role of CMR to conventional screening in the diagnosis and prognosis of cardiac sarcoidosis. JACC Cardiovasc Imaging. 2017;10(12):1437–1447. doi: 10.1016/j.jcmg.2016.11.019
   PubMed Web of Science ®Google Scholar
• Hirose Y, Ishida Y, Hayashida K, et al. Myocardial involvement in patients with sarcoidosis. An analysis of 75 patients. Clin Nucl Med. 1994;19(6):522–526. doi: 10.1097/00003072-199406000-00012
   PubMed Web of Science ®Google Scholar
• Yamagishi H, Shirai N, Takagi M, et al. Identification of cardiac sarcoidosis with (13)N-NH(3)/(18)F-FDG PET. J Nucl Med. 2003;44(7):1030–1036.
   PubMed Web of Science ®Google Scholar
• Fussner LA, Karlstedt E, Hodge DO, et al. Management and outcomes of cardiac sarcoidosis: a 20-year experience in two tertiary care centres. Eur J Heart Fail. 2018;20(12):1713–1720. doi: 10.1002/ejhf.1319
   PubMed Web of Science ®Google Scholar
• Kandolin R, Lehtonen J, Airaksinen J, et al. Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation. 2015;131(7):624–632. doi: 10.1161/CIRCULATIONAHA.114.011522
   PubMed Web of Science ®Google Scholar
• Ekstrom K, Lehtonen J, Nordenswan HK, et al. Sudden death in cardiac sarcoidosis: an analysis of nationwide clinical and cause-of-death registries. Eur Heart J. 2019;40(37):3121–3128. doi: 10.1093/eurheartj/ehz428
   PubMed Web of Science ®Google Scholar
• Rosen NS, Pavlovic N, Duvall C, et al. Cardiac sarcoidosis outcome differences: a comparison of patients with de novo cardiac versus known extracardiac sarcoidosis at presentation. Respir med. 2022;198:106864. doi: 10.1016/j.rmed.2022.106864
   PubMed Web of Science ®Google Scholar
• Tana C, Drent M, Nunes H, et al. Comorbidities of sarcoidosis. Ann Med. 2022;54(1):1014–1035. doi: 10.1080/07853890.2022.2063375
   PubMed Web of Science ®Google Scholar